Depemokimab for COPD with type 2 inflammation
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a new biologic medicine, given as an injection, to see if it can reduce flare-ups in adults with COPD who have a certain type of inflammation. It may help people who still have frequent exacerbations despite using their current inhalers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old
- You have a diagnosis of moderate to severe COPD for at least 1 year
- Your blood tests show high eosinophils (a type of white blood cell linked to inflammation)
- You have had at least 2 moderate or 1 severe COPD flare-up in the last year
- You are a current or former smoker with at least a 10 pack-year smoking history
- You have been on a combination inhaler (ICS/LAMA/LABA) for at least 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new biologic medicine called depemokimab, given as an injection, to see if it reduces flare-ups (exacerbations) in people with COPD who have a specific type of inflammation (high eosinophils). It may help if you have frequent flare-ups despite using your regular inhalers.
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
This study tests a new medication called tezepelumab (given as a shot) to see if it can reduce COPD flare-ups in people with moderate to very severe COPD who have had recent flare-ups despite using inhalers. It may be an option for those with higher levels of eosinophils (a type of white blood cell) in their blood.
Hear when a new Pulmonary Disease, Chronic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.